Access count of this item: 278

Files in This Item:
File Description SizeFormat 
46_247.pdf2.8 MBAdobe PDFView/Open
Title: 厚型電極VaporTomeを用いた経尿道的前立腺手術に関する臨床的検討
Other Titles: Clinical study of transurethral surgery for benign prostatic hyperplasia using a thick loop (VaporTome)
Authors: 矢島, 通孝  KAKEN_name
馬場, 克幸  KAKEN_name
柳澤, 直子  KAKEN_name
西田, 智保  KAKEN_name
山川, 克典  KAKEN_name
武村, 宏  KAKEN_name
西田, 茂史  KAKEN_name
岩本, 晃明  KAKEN_name
Author's alias: YAJIMA, Michitaka
BABA, Katsuyuki
NISHIDA, Takayasu
YAMAKAWA, Katsunori
NISHIDA, Shigehito
IWAMOTO, Teruaki
Keywords: Prostate
Benign prostatic hyperplasia
Transurethral surgery
Issue Date: Apr-2000
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 46
Issue: 4
Start page: 247
End page: 250
Abstract: VaporTomeTMを使用した経尿道的前立腺手術は,通常のループ型電極と比較して,ほぼ同様の優れた治療効果を有している.切除組織重量はループ型電極よりは少ないものの,病理学的診断には十分な量の組織の採取が可能である.他の低侵襲治療法と比較して,通常の切除鏡と電気メスが使用できるため経済効率の面からも優れていると考える
From December 1996 to June 1998, we performed transurethral surgery of the prostate using a thick loop, VaporTome developed by Circon ACMI on 23 patients with symptomatic benign prostatic hyperplasia (BPH). The mean international prostate symptom score decreased significantly, from 22.6 at baseline to 9.0, 6.5, 4.9 and 5.3 at 1, 3, 6 and 12 months after operation, respectively. The mean quality of life index also decreased significantly, from 5.5 to 1.8, 1.8, 1.4 and 1.2, respectively. The mean peak flow rate increased significantly, from 6.2 preoperatively to 15.8, 17.1, 16.6 and 17.4 ml/sec at 1, 3, 6 and 12 months after operation, respectively. The mean prostate volume decreased significantly, from 66.9 to 24.8, 17.3, 19.0 and 18.2 ml. The mean residual urine decreased significantly, from 167.9 to 11.4, 9.4, 12.8 and 20.4 ml. As for overall efficacy, the rate of excellent and good cases at 1, 3, 6 and 12 months was 80.9, 89.4, 94.7 and 85.8%, respectively. No serious complications were observed. Our clinical results suggest that transurethral surgery for BPH using VaporTome has several potential advantages including high efficacy, minimal morbidity compared with standard transurethral resection of the prostate and lower cost compared with other minimally invasive procedures.
PubMed ID: 10845155
Appears in Collections:Vol.46 No.4

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.